Choroideremia is what happens when three retinal layers — the choroid underneath, the retinal pigment epithelium above it, and the photoreceptors sitting on top of that — degenerate together as a unit rather than separately. It’s carried on the X chromosome, and that inheritance pattern means it shows up almost exclusively in boys and men; women who carry the gene generally get away with only minor changes that rarely interfere with everyday vision.
For families coming to us from Uganda, the road to a choroideremia diagnosis often starts with a routine fundus photo on a male relative that struck a local ophthalmologist as slightly ‘off’ for ordinary RP. That instinct is usually correct — the appearance is distinctive enough that it’s worth confirming with genetic testing rather than filing it under a generic retinal dystrophy label.
The opening sign is almost always night blindness that starts in childhood, well ahead of any other change. From there, the field of vision narrows steadily across the teenage years and into adult life. The feature that really distinguishes choroideremia is just how long central vision manages to survive — commonly for several decades longer than in most other inherited retinal diseases — though it isn’t permanent, and can eventually be lost once the degeneration reaches the macula in mid-to-late adulthood.
The culprit is the CHM gene, carried on the X chromosome, and its loss means cells across the choroid, RPE, and photoreceptor layers run short of a protein called REP1 that they need to keep functioning. Because it’s X-linked, a mother who carries the mutation passes it to roughly half her sons, who go on to be affected, and to roughly half her daughters, who become carriers in turn.
On fundus examination, choroideremia tends to produce a fairly recognisable scalloped appearance as the choroid and RPE waste away, and paired with electroretinography and OCT scans, that pattern is usually enough to set it apart from other rod-cone dystrophies at a fairly early stage. Genetic testing for CHM mutations settles the question definitively, and is particularly valuable for checking carrier status in female relatives.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Given how long central vision tends to hold on in choroideremia, treatment leans heavily toward preserving retinal function for as much of that window as possible. We weigh regenerative stem cell therapy for suitable candidates as part of that plan, alongside ongoing monitoring of how the degeneration is advancing and early low-vision planning ahead of the central-vision changes that may eventually come.
“It’s a matter of X-chromosome genetics. Men have only one X chromosome, so a single faulty CHM gene is enough to cause the condition outright. Women have two X chromosomes, and the working copy in carriers is generally enough to keep vision largely intact, aside from occasional mild changes.”
“Not with certainty — statistically, each son has about a fifty-fifty chance of inheriting the mutation, and each daughter has about a fifty-fifty chance of becoming a carrier herself. Genetic testing can narrow that down for your family specifically.”
“
Often, yes — the scalloped pattern affecting both the choroid and RPE together looks fairly different from the more even photoreceptor loss typical of classic RP, and an experienced examiner can usually pick up on that. Genetic testing is still what provides the final confirmation.”
“Sooner rather than later — starting early keeps the most options on the table while central vision is still working well. We’d rather see a patient for a specialist assessment before central-vision symptoms show up than wait until they do.”
